Integrated Solutions from Research to Commercialisation.
Almac is a financially secure, privately owned organisation with over 3,300 employees located within the US and UK. Over 600 companies worldwide, including all the market leaders, use our services, testament itself to the quality, innovation and efficiency of our business as proven over the past 30+ years.
Our vast range of services include:
Biomarker Discovery & Development: Pre-clinical biomarker discovery, through to full companion diagnostic development and clinical test delivery from our CLIA laboratory.
API Services & Chemical Development: Services for all stages of drug development for small molecules, potent and cytotoxic compounds and peptides.
Pharmaceutical Development: Developing clinical candidates into an optimum formulation and manufacturing drug product for all phases of clinical trial supply.
Analytical Services: Delivering comprehensive solutions supporting drug substance and product development programmes.
Clinical Trial Supply: Offering over 20 years experience in clinical supply, packaging, distribution and management.
Clinical Technologies: Providing interactive voice and web response technologies, flexible solutions for patient enrollment, electronic PROs and adaptive trials.
Commercial Services: Services for all drug products from manufacturing, testing and packaging to end-user distribution.
Almac – Partnering to Advance Human Health™
Mr Gildas Lavenant
Mr Philip Diamond
Mr Philip Berry
Mr Glyn Allsop
Mr Simon LawrenceGalen Ltd
Dr Rob GrundyAlmac Discovery
Astex Pharmaceuticals™ is a leader in innovative drug discovery, development and commercialization, committed to the fight against cancer and other life-threatening diseases.
- Fiscal strength with significant cash, ongoing revenues and potential milestone payments
- Productive partnerships with top-tier pharmaceutical companies
- Rich product portfolio with multiple drugs in clinical development
- Visionary leadership backed by a world-class management team
We are a leader in innovative small-molecule therapeutics with particular expertise in fragment-based drug discovery, the most important advance in discovery chemistry in the last 20 years. Our primary areas of focus are oncology and hematology.Financially Strong
We are a publicly traded pharmaceutical company with strong cash reserves and royalty revenues from the sales of our product DACOGEN®. In addition, our partnerships could deliver nearly $2 billion in product milestones plus royalties.